The alpha7 nicotinic acetylcholine receptor mediates network dysfunction in a mouse model of local amyloid pathology
- 23 September 2025
- journal article
- research article
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (3) , 1293-1310
Abstract
Patient and animal model data suggest a link between the cholinergic neuromodulatory system and the amyloid beta (Aβ) peptide in causing Alzheimer’s disease (AD). But how cholinergic dysfunctions contribute to AD pathology remains controversial. In a mouse model of local amyloid pathology, we show that in the early disease stages, the α7 nicotinic acetylcholine receptor (nAChR) is an important target of Aβ in the prefrontal cortex (PFC). Using in vivo two-photon calcium imaging and in vivo patch-clamp electrophysiology in the PFC of awake mice, we demonstrate that Aβ-mediated disruption of specifically the α7 nAChR subunit, expressed by distinct interneuron subtypes, results in substantial deficits in network activity. This is corroborated by electrophysiology experiments in slices. Combined with computational modeling, we propose that α7 nAChRs are occluded by Aβ early in the disease, whereas the heteropentameric α5 and β2 nAChRs are only partially inactivated and potentially provide novel therapeutic targets for intervention. Accordingly, we show that galantamine, an approved acetylcholine-esterase inhibitor (AChE-I), which acts as a positive allosteric modulator (PAM) of α5-containing nAChRs at low concentrations, reduces neuronal hyperactivity.Keywords
This publication has 84 references indexed in Scilit:
- Concatemers to re-investigate the role of α5 in α4β2 nicotinic receptorsCellular and Molecular Life Sciences, 2020
- Neuronal hyperactivity – A key defect in Alzheimer's disease?BioEssays, 2015
- Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's diseaseBiochemical Pharmacology, 2011
- Allosteric Modulator Desformylflustrabromine Relieves the Inhibition of α2β2 and α4β2 Nicotinic Acetylcholine Receptors by β-Amyloid1–42 PeptideJournal of Molecular Neuroscience, 2011
- PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer’s diseasePsychopharmacology, 2006
- Cholinesterase inhibitors for Alzheimer's diseaseCochrane Database of Systematic Reviews, 2006
- In vivo, low-resistance, whole-cell recordings from neurons in the anaesthetized and awake mammalian brainPflügers Archiv - European Journal of Physiology, 2002
- Purinergic inhibition of GABA and glutamate release in the thalamus: Implications for thalamic network activityNeuron, 1995
- Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brainsNeuroscience Letters, 1986
- Nicotinic acetylcholine binding sites in Alzheimer's diseaseBrain Research, 1986